AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20082244 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulian Ointment (NPLO)
Number of subjects: 108
Study 20082244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 16696418 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 liters/minute flow of 100% oxygen via tubes attached to the upper chest walls (group 1)
Number of subjects: 80
Study 16696418 — intervention group
Group type: COMPARATOR
Intervention: Sham oxygenation (group 2)
Number of subjects: 80
Study 15477799 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (specific dosage and duration not mentioned)
Number of subjects: 0
Study 11701672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Number of subjects: 0
Study 11701672 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 0
Study 9152565 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ketorolac
Number of subjects: 157
Study 9152565 — intervention group
Group type: COMPARATOR
Intervention: 1% prednisolone acetate
Number of subjects: 157
Study 9152565 — intervention group
Group type: COMPARATOR
Intervention: 0.1% dexamethasone
Number of subjects: 157
Study 7954250 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (60 mg/m2 on Days 1-3 for the first course; 60 mg/m2 on Days 1-4 for the second course; 60 mg/m2 on Days 1-5 for the third course, recycled every 3 weeks)
Number of subjects: 65
Study 7954250 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vinblastine (3 mg/m2 weekly for 3 weeks, then 6 mg/m2 every 3 weeks)
Number of subjects: 65
Study 3601828 — intervention group
Group type: EXPERIMENTAL
Intervention: AGM disposable diapers
Number of subjects: 0
Study 3601828 — intervention group
Group type: COMPARATOR
Intervention: Conventional disposable diapers
Number of subjects: 0
Study 3601828 — intervention group
Group type: COMPARATOR
Intervention: Home-laundered cloth diapers
Number of subjects: 0
Study 29470614 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttherapy PET/CT scans (positive, equivocal, negative)
Number of subjects: 55
Study 27965864 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for depersonalisation, delivered over six sessions within a maximum of 10 weeks.
Number of subjects: 0
Study 27965864 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control condition)
Number of subjects: 0
Study 26380438 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment group (needling at Zusanli, Yanglingquan, Neiguan, Guanyuan, once per day for 6 days)
Number of subjects: 90
Study 26380438 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha1 group (subdermal injection of thymosin alpha1 1.6 mg, once per day for 6 days)
Number of subjects: 90
Study 26380438 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment according to Surviving Sepsis Campaign guidelines)
Number of subjects: 90
Study 23782493 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient piece of candy prior to every infusion during three chemotherapy cycles
Number of subjects: 52
Study 23782493 — intervention group
Group type: COMPARATOR
Intervention: Flavorless placebo tablets
Number of subjects: 52
Study 21934637 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 21
Study 21934637 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil
Number of subjects: 21
Study 21934637 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg udenafil
Number of subjects: 21
Study 19455176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched drink (twice a day for 24 weeks)
Number of subjects: 176
Study 19455176 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (twice a day for 24 weeks)
Number of subjects: 176
Study 19455176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-enriched drink
Number of subjects: 176
Study 19455176 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 176
Study 16495423 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage nurse judgment (RN JDGMT)
Number of subjects: 3790
Study 16495423 — intervention group
Group type: COMPARATOR
Intervention: Triage prediction rule (PRD)
Number of subjects: 3790
Study 16495423 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream (lidocaine 2.5% and prilocaine 2.5%) applied to 'IV likely' patients
Number of subjects: 3790
Study 15545150 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultatory sphygmomanometric method with sleeves
Number of subjects: 201
Study 15545150 — intervention group
Group type: COMPARATOR
Intervention: Auscultatory sphygmomanometric method without sleeves
Number of subjects: 201
Study 15545150 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic oscillometric method with sleeves
Number of subjects: 201
Study 15545150 — intervention group
Group type: COMPARATOR
Intervention: Automatic oscillometric method without sleeves
Number of subjects: 201
Study 10868699 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ferritin concentration >70 microg/liter
Number of subjects: 733
Study 10868699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of iron and red meat
Number of subjects: 733
Study 10868699 — intervention group
Group type: EXPERIMENTAL
Intervention: Log ferritin concentration
Number of subjects: 733
Study 7698064 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional small group education for 2 months
Number of subjects: 0
Study 7698064 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual supplementary education for 2 months
Number of subjects: 0
Study 7698064 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacist instruction (Control)
Number of subjects: 0
Study 7698064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 0
Study 2764526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 295
Study 2764526 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin with probenecid
Number of subjects: 295
Study 800381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (600-800 mg/day)
Number of subjects: 40
Study 800381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen once a day at bedtime
Number of subjects: 40
Study 800381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen twice a day
Number of subjects: 40
Study 800381 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin three times a day
Number of subjects: 40
Study 800381 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen (both dosing regimens)
Number of subjects: 40
Study 31311761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + FOLFOX-4 then bevacizumab-5-FU-radiotherapy (RT) before total mesorectal excision (TME) (arm A)
Number of subjects: 91
Study 31311761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-5-FU-RT then TME (arm B)
Number of subjects: 91
Study 31311761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + FOLFOX-4 then bevacizumab-5-FU-RT (arm A)
Number of subjects: 91
Study 27327391 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lap‐tray during sitting and triangular sling while standing
Number of subjects: 46
Study 27327391 — intervention group
Group type: COMPARATOR
Intervention: Hemi‐sling while sitting and standing
Number of subjects: 46
Study 26176592 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pdm09 vaccine (1.9 µg HA and AS03B)
Number of subjects: 314
Study 26176592 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pdm09 vaccine (3.75 µg HA and AS03A)
Number of subjects: 314
Study 26176592 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A(H1N1)pdm09 vaccine
Number of subjects: 314
Study 25098377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive vitamin D therapy (alfacalcidiol 0.25 mcg orally with each dialysis session + ergocalciferol 50,000 IU orally once per week)
Number of subjects: 60
Study 25098377 — intervention group
Group type: COMPARATOR
Intervention: Standard vitamin D therapy (alfacalcidiol 0.25 mcg orally + placebo each dialysis session)
Number of subjects: 60
Study 25098377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive vitamin D therapy
Number of subjects: 60
Study 25098377 — intervention group
Group type: COMPARATOR
Intervention: Standard vitamin D therapy
Number of subjects: 60
Study 22743176 — intervention group
Group type: COMPARATOR
Intervention: PPC heparin
Number of subjects: 21
Study 22743176 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepalean
Number of subjects: 21
Study 19056602 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5-h bedtime condition
Number of subjects: 11
Study 19056602 — intervention group
Group type: COMPARATOR
Intervention: 8.5-h bedtime condition
Number of subjects: 11
Study 17136398 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 2
Study 17136398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 15784148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium Rub (80% ethanol)
Number of subjects: 20
Study 15784148 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagard (61% ethanol and 1% chlorhexidine gluconate)
Number of subjects: 20
Study 15784148 — intervention group
Group type: COMPARATOR
Intervention: Reference treatment (n-propanol, 60% v/v)
Number of subjects: 20
Study 12461496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatricians' attitudes toward children's participation in RCTs
Number of subjects: 21
Study 12461496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatricians' beliefs and relationship with investigators
Number of subjects: 21
Study 12461496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatricians with previous research experience
Number of subjects: 21
Study 12461496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatricians' personal treatment preferences
Number of subjects: 21
Study 12461496 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and involvement in trials for pediatricians
Number of subjects: 21
Study 9806121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunbathing
Number of subjects: 2615
Study 9806121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunbed use
Number of subjects: 2615
Study 9806121 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived susceptibility to melanoma
Number of subjects: 2615
Study 9806121 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for sunbathing
Number of subjects: 2615
Study 8603262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fish oil (MaxEPA 18 g/day) for 10 weeks
Number of subjects: 20
Study 8603262 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented group of men with AIDS wasting
Number of subjects: 20
Study 1759538 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 5 x 10(6) units thrice weekly for 4 months
Number of subjects: 24
Study 1759538 — intervention group
Group type: COMPARATOR
Intervention: Interferon 0.25 x 10(6) U thrice weekly for 6 months (low dose)
Number of subjects: 24
Study 1759538 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 3 x 10(6) U thrice weekly for 6 months (high dose)
Number of subjects: 24
Study 7044649 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg single dose)
Number of subjects: 6
Study 7044649 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg repeated doses bid)
Number of subjects: 6
Study 7044649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7044649 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1 week treatment)
Number of subjects: 6
Study 7044649 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (S and R doses) during dynamic physical activity (DPA)
Number of subjects: 6
Study 7044649 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (S and R doses) during DPA
Number of subjects: 6
Study 30452533 — intervention group
Group type: EXPERIMENTAL
Intervention: High-to-moderate-low systolic BP trajectory
Number of subjects: 4036
Study 30452533 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-high systolic BP trajectory
Number of subjects: 4036
Study 30452533 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-low systolic BP trajectory
Number of subjects: 4036
Study 30452533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low systolic BP trajectory
Number of subjects: 4036
Study 27663098 — intervention group
Group type: EXPERIMENTAL
Intervention: Proenkephalin (pro-ENK)
Number of subjects: 1684
Study 25798575 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of statin therapy
Number of subjects: 381
Study 25798575 — intervention group
Group type: COMPARATOR
Intervention: Continuation of statin therapy
Number of subjects: 381
Study 23913868 — intervention group
Group type: EXPERIMENTAL
Intervention: Small airway deposition of dornase alfa
Number of subjects: 38
Study 23913868 — intervention group
Group type: COMPARATOR
Intervention: Large airway deposition of dornase alfa
Number of subjects: 38
Study 22506302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rockumentary music therapy intervention
Number of subjects: 141
Study 22506302 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational music therapy
Number of subjects: 141
Study 22506302 — intervention group
Group type: EXPERIMENTAL
Intervention: Rockumentary music therapy
Number of subjects: 141
Study 22506302 — intervention group
Group type: COMPARATOR
Intervention: Verbal therapy
Number of subjects: 141
Study 19150064 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day (A80)
Number of subjects: 58
Study 19150064 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg + Ezetimibe 10 mg per day (A10E10)
Number of subjects: 58
Study 17803058 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 24
Study 15197202 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative external-beam radiotherapy with boost (85 Gy in three fractions) using endocavitary contact x-ray
Number of subjects: 88
Study 15197202 — intervention group
Group type: COMPARATOR
Intervention: Preoperative external-beam radiotherapy (39 Gy in 13 fractions over 17 days)
Number of subjects: 88
Study 15197202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 11826764 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐follitropin
Number of subjects: 20
Study 11826764 — intervention group
Group type: COMPARATOR
Intervention: beta‐follitropin
Number of subjects: 20
Study 11826764 — intervention group
Group type: COMPARATOR
Intervention: urofollitropin
Number of subjects: 20
Study 11826764 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (alpha‐follitropin, beta‐follitropin, urofollitropin)
Number of subjects: 20
Study 9512151 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbus-based conjunctival flap
Number of subjects: 69
Study 9512151 — intervention group
Group type: COMPARATOR
Intervention: Fornix-based conjunctival flap
Number of subjects: 69
Study 7869212 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.65 ± 0.07 IU.kg‐1.wk‐1) and gonadotropin-releasing hormone analogs (66 ± 9 micrograms.kg‐1 every 28 days)
Number of subjects: 7
Study 7869212 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone administered alone after interruption of gonadotropin-releasing hormone analogs
Number of subjects: 7
Study 7869212 — intervention group
Group type: COMPARATOR
Intervention: Control group (seven untreated girls)
Number of subjects: 7
Study 2531718 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-hANP administration
Number of subjects: 12
Study 2531718 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-treatment
Number of subjects: 12
Study 3086 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (Temesta)
Number of subjects: 55
Study 3086 — intervention group
Group type: COMPARATOR
Intervention: Complete placebo (orally and by vaccine)
Number of subjects: 55
Study 31970393 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal glove and gown use
Number of subjects: 20246
Study 31628558 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Nd:YAG laser therapy (1500 J total energy, thrice/week for four weeks)
Number of subjects: 40
Study 31628558 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy plus physical exercise program
Number of subjects: 40
Study 30940164 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (VPA) delivered during secondary school physical education (PE) - an additional 10 min of VPA per PE lesson for one academic year.
Number of subjects: 0
Study 30940164 — intervention group
Group type: COMPARATOR
Intervention: PE as usual (control condition).
Number of subjects: 0
Study 28472383 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 1669
Study 28472383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1669
Study 26306736 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm bracing posture
Number of subjects: 16
Study 22821223 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance with mandibular advancement (active group)
Number of subjects: 72
Study 22821223 — intervention group
Group type: COMPARATOR
Intervention: Oral appliance without advancement (control group)
Number of subjects: 72
Study 22019126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy guided endometrial biopsy
Number of subjects: 678
Study 22019126 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without endometritis)
Number of subjects: 678
Study 17868383 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 ng/m(2) body surface area of synthetic ACTH
Number of subjects: 6
Study 17868383 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ng/m(2) body surface area of synthetic ACTH
Number of subjects: 6
Study 17868383 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ng/m(2) body surface area of synthetic ACTH
Number of subjects: 6
Study 16949482 — intervention group
Group type: COMPARATOR
Intervention: 300 mg clopidogrel loading dose
Number of subjects: 103
Study 16949482 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 103
Study 16949482 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg clopidogrel loading dose
Number of subjects: 103
Study 16949482 — intervention group
Group type: EXPERIMENTAL
Intervention: All clopidogrel doses
Number of subjects: 103
Study 12940611 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 15 mg/kg following dialysis (Phase I)
Number of subjects: 9
Study 12940611 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 15 mg/kg during the last hour of hemodialysis (Phase II)
Number of subjects: 9
Study 12940611 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 30 mg/kg during the last 2 hours of hemodialysis (Phase III)
Number of subjects: 9
Study 10852529 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (875/125 mg) administered orally 2 to 4 hours before surgery
Number of subjects: 23
Study 10852529 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin alone (implied as a comparison)
Number of subjects: 23
Study 9488196 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (Norvasc), a third generation calcium channel blocker (CCB)
Number of subjects: 0
Study 9488196 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (Norvasc)
Number of subjects: 0
Study 9488196 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0
Study 8450247 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MIU of systemic recombinant interferon-alpha 2a given three times weekly for 4 weeks after CO2 laser ablation
Number of subjects: 130
Study 3698458 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg/kg for 15 days followed by 0.3 mg/kg for 7 days)
Number of subjects: 0
Study 3698458 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (0.8 mg/kg for 15 days followed by 1.2 mg/kg for 7 days)
Number of subjects: 0
Study 3698458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3698458 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam and Oxazepam (both)
Number of subjects: 0
Study 30632321 — intervention group
Group type: EXPERIMENTAL
Intervention: Social attention training game
Number of subjects: 66
Study 30632321 — intervention group
Group type: COMPARATOR
Intervention: Control game
Number of subjects: 66
Study 29481695 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle ear implants (MEIs)
Number of subjects: 91
Study 29481695 — intervention group
Group type: COMPARATOR
Intervention: Conventional hearing aids (HAs)
Number of subjects: 91
Study 26613955 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea (Arctic Root) for 14 days pretreatment
Number of subjects: 13
Study 26613955 — intervention group
Group type: COMPARATOR
Intervention: Control (without Rhodiola rosea)
Number of subjects: 13
Study 24617812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum OLB6378 (B. bifidum)
Number of subjects: 283
Study 24617812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 22273743 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etch adhesive (Silorane System Adhesive, 3M ESPE: SSA) with low-shrinking composite (Filtek Silorane, 3M ESPE: FS)
Number of subjects: 5
Study 22273743 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (G-Bond, GC) with low-shrinking composite (N'Durance, Septodont: N'D)
Number of subjects: 5
Study 22273743 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (G-Bond, GC) with low-shrinking composite (Kalore, GC: Ka)
Number of subjects: 5
Study 22273743 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (G-Bond, GC) with conventional composite (Z100, 3M ESPE)
Number of subjects: 5
Study 22273743 — intervention group
Group type: EXPERIMENTAL
Intervention: Layering method with all composites
Number of subjects: 5
Study 22273743 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etch adhesive (Silorane System Adhesive, 3M ESPE: SSA) with conventional composite (Z100, 3M ESPE)
Number of subjects: 5
Study 20630169 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Labels
Number of subjects: 47
Study 20630169 — intervention group
Group type: COMPARATOR
Intervention: No Labels
Number of subjects: 47